APA (7th ed.) Citation

J, P., K, W., H, E., J, K., A, M., N, B., . . . BC, B. (2021). Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(10), 2712. https://doi.org/10.1158/1078-0432.CCR-20-4725

Chicago Style (17th ed.) Citation

J, Pidala, et al. "Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention After Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 27, no. 10 (2021): 2712. https://doi.org/10.1158/1078-0432.CCR-20-4725.

MLA (9th ed.) Citation

J, Pidala, et al. "Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention After Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 27, no. 10, 2021, p. 2712, https://doi.org/10.1158/1078-0432.CCR-20-4725.